Organization (Industry)
Vericel Corp
ClinicalTrials.gov lists Vericel Corp as lead sponsor of 14 trials. It has 3 active development programs and 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Vericel Corp: 14 lead-sponsored trials and 1 legal-entity registration.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Fractures, Bone | 3 |
| Atherosclerosis | 2 |
| Cardiomyopathies | 2 |
| Cardiomyopathy, Dilated | 2 |
| Cartilage Diseases | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2018 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 1 |
| 2009 | 1 |
| 2008 | 3 |
| 2007 | 2 |
| 2006 | 1 |
| 2003 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| autologous cultured chondrocytes on porcine collagen membrane | Cartilage Diseases | Phase 3 | 1 |
| Bone Marrow Stimulation | Cartilage Diseases | Phase 3 | 1 |
| MACI | Osteochondritis Dissecans | Phase 3 | 1 |
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Carticel (autologous cultured chondrocyte) implantation | 2 |
| MACI | 1 |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of periodontology | 5 |
| The International journal of oral & maxillofacial implants | 3 |
| Acta orthopaedica Scandinavica | 2 |
| Annals of periodontology | 2 |
| Bone marrow transplantation | 2 |
Showing 5 of 34 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 20 | 3 | 2025-12-16 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 276,259,000 | 16,518,000 | 27,563,000 |
| 2024 | 237,224,000 | 10,362,000 | 24,797,000 |
| 2023 | 197,516,000 | -3,182,000 | 21,042,000 |
| 2022 | 163,698,000 | -16,709,000 | 19,943,000 |
| 2021 | 153,075,000 | -7,471,000 | 16,287,000 |
| 2020 | 121,968,000 | 2,864,000 | 13,020,000 |
| 2019 | 117,850,000 | -9,665,000 | 30,391,000 |
| 2018 | 90,857,000 | -8,137,000 | 13,599,000 |
| 2017 | 62,760,000 | -17,286,000 | 12,944,000 |
| 2016 | 54,383,000 | -19,566,000 | 15,295,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (5)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-30 | Other financing | not disclosed | Sec extracted |
| 2024-08-16 | Follow-on offering | not disclosed | Edgar offerings |
| 2022-07-29 | Debt financing | not disclosed | Sec extracted |
| 2021-08-27 | Other financing | not disclosed | Edgar offerings |
| 2021-08-27 | ATM offering | not disclosed | Sec extracted |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 6 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Vericel Corporation | CAMBRIDGE, US | FDA | |
| Vericel Corporation | Burlington, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (47)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-30 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-09-25 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-08-16 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 47 events.
Biomarker capability evidence (23)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AGTR1 | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial sponsor | Primary endpoint in a Phase 3 trial |
| NPPB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 23 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, fda warning letters, fda untitled letters, fda recalls, fda import refusals, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.